SuperworthMannkind EPS MNKD
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.13
- Latest quarter, Q2 FY26
- −$0.06
- Fiscal year 2025
- $0.02
- −80% on the year before
Mannkind's earnings per share was −$0.13 over the twelve months to Jun 30, 2026, down 218% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.06.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.02 | −80% |
| FY2024 | $0.10 | n/a |
| FY2023 | −$0.04 | n/a |
| FY2022 | −$0.34 | n/a |
| FY2021 | −$0.32 | n/a |
| FY2020 | −$0.25 | n/a |
| FY2019 | −$0.27 | n/a |
| FY2018 | −$0.63 | n/a |
| FY2017 | −$1.11 | −189% |
| FY2016 | $1.25 | n/a |
| FY2015 | −$4.45 | n/a |
| FY2014 | −$2.55 | n/a |
| FY2013 | −$3.20 | n/a |
| FY2012 | −$4.75 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.06 | n/a | −$0.13 | |
| Q1 FY26 | −$0.05 | −225% | −$0.07 | |
| Q4 FY25 | −$0.05 | −267% | $0.02 | |
| Q3 FY25 | $0.03 | −25% | $0.10 | |
| Q2 FY25 | $0.00 | n/a | $0.11 | |
| Q1 FY25 | $0.04 | +0% | $0.10 | |
| Q4 FY24 | $0.03 | +200% | $0.10 | |
| Q3 FY24 | $0.04 | +300% | $0.08 | |
| Q2 FY24 | −$0.01 | n/a | $0.05 | |
| Q1 FY24 | $0.04 | n/a | $0.04 | |
| Q4 FY23 | $0.01 | n/a | −$0.04 | |
| Q3 FY23 | $0.01 | n/a | −$0.12 |
Against its peers
Companies in Drug Manufacturers - General nearest Mannkind's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MNKDMannkind | −$0.13 | −218% a year |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| ABUSArbutus Biopharma | $0.78 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| Peer median | $1.61 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Mannkind
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.